Inka Health Selected by OneMedNet to Lead AI-Driven Oncology Project Using Real-World Data for External Control Arms

Executive Summary

• Onco-Innovations Limited’s wholly owned subsidiary, Inka Health Corp., has been selected by OneMedNet Corporation to lead a high-impact data analytics initiative focused on developing external control arms (ECAs) for cancer therapies.
• The project aims to leverage OneMedNet’s regulatory-grade patient data and Inka Health’s proprietary SynoGraph platform to create faster, more cost-effective alternatives to traditional clinical trials, specifically targeting non-small cell lung cancer (NSCLC).
• The collaboration is expected to produce a scientific abstract for submission to ISPOR Europe 2025, positioning Onco and Inka Health at the forefront of the Real-World Evidence (RWE) market, which is projected to exceed $4.6 billion globally by 2030.

Key Details

• Parties Involved: Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and its subsidiary Inka Health Corp.; OneMedNet Corporation (Nasdaq: ONMD).
• Project Scope: Development of external control arms (ECAs) using real-world data (RWD) to replicate traditional clinical trial results, reducing time, cost, and complexity.
• Specific Application: Initial focus on replicating results of the Keynote-189 trial for pembrolizumab in non-small cell lung cancer (NSCLC).
• Technology: Inka Health will deploy its proprietary SynoGraph platform, which combines machine learning with causal inference methods.
• Regulatory Alignment: The initiative aligns with best practices from the FDA, European Medicacy Agency (EMA), and National Institute for Health and Care Excellence (NICE).
• Market Context: The project targets the Real-World Evidence (RWE) market, projected to exceed $4.6 billion globally by 2030.
• Deliverables: The collaboration is expected to result in a scientific abstract for submission to ISPOR Europe 2025.
• Strategic Goal: Accelerate market entry for new cancer therapies, particularly in areas of high unmet needs like colorectal cancer, and improve regulatory and reimbursement confidence.

Notable Quotes

• Aaron Green, President & CEO of OneMedNet: “We selected Inka Health for this initiative because their methodological approach aligns perfectly with our vision for high-quality evidence generation... Their ability to apply rigorous, AI-driven analytics to our regulatory-grade, diverse datasets makes them the ideal partner to showcase how OneMedNet’s Real-World Data can be used as a trusted external control arm in oncology research—with the potential to help pharmaceutical companies realize a stronger ROI on clinical development...”
• Paul Arora, Co-Founder of Inka Health: “This collaboration is about more than applying advanced analytics to oncology data. It's about reshaping how we generate credible evidence for regulatory and reimbursement decisions using real-world patients, not just trial participants. With SynoGraph, we’re aiming to set a new bar for how external control arms can be built and trusted.”